The impact of hypernasality on the perception of prosody

Hypernasality is a speech disorders that results from excessive sound coming through the nose during speech. A speaker afflicted with hypernasality may be perceived as sounding flat and monotonous because the nasal murmur masks the inflections of the fundamental frequency (Kummer, 2008). However, the masking of prosody by the nasal murmur has not been investigated systematically. The first goal of the proposed study is to investigate how the presence of hypernasality affects the listener’s perception of prosodic pitch inflections.

Preclinical proof of concept study evaluating PBI-4050 and analogs as potential treatments in the context of ischemic cardiomyopathy

The ability to impede/reduce complication of the damaged heart presents a major challenge in the treatment of cardiovascular diseases. Complications include heart failure, which has a high mortality even with current treatments. The use of a new drug to stimulate protection of the heart during an ongoing myocardial infarct and long term changes leading to heart failure would be very relevant to the clinical setting, to help patients suffering from diverse heart problems.

A Pilot Project to Assess the Pharmacoeconomic Feasibility ofSubcutaneous Immunoglobulin for Neuromuscular Diseases

For the management of neuromuscular disorders (NMD), subcutaneous immunoglobulin (SCIg) administration has become an alternate option, being a home-based alternative to conventional intravenous immunoglobulin (IVIg), with a comparable efficacy, minimum adverse effects and significant improvement to the quality of life. With the increased cost of healthcare management, it has become more challenging for clinicians and other healthcare decision makers to come up with a better alternative while considering economics factors, though as a secondary.

Genetic profiling of disease progression in myeloma

The intern will be studying the way genetics are changed during the progression of multiple myeloma and cancers in general. The changes in the genetic profile will help understand the disease. Throughout the project, genetic alterations of chromosome ends, known as telomeres, will be analyzed through complex mathematical and computational 3D architectural softwares to predict how certain cancer patients will do in the future or even if they will respond to certain medications.

Processing of Linac Produced 99Mo, and Extraction and Validation of 99mTc using a unique 99Mo/99mTc generator system

Technetium-99m (99mTc) is a radioactive substance that is used in nuclear medicine departments worldwide. This substance when made in an appropriate formulation is injected in patients and following its decay pictures of the patient can be obtained. This pictures help physicians diagnose certain diseases notably cancers and heart diseases. The government of Canada historically was the main producer of this radioactive substance. Due to the aging of the machines that are used to produce these substance the government announced that in 2019 it will no longer be producing Tc-99m.

SSI efficacy in treating infectious colitis

Inflammatory bowel disease (IBD) is a disease with unknown etiology that is characterized by uncontrolled intestinal inflammation and microbial dysbiosis. Qu Biologics’ Site Specific Immunomodulators (SSI) are a platform technology shown to improve the status of people living with IBD (Crohn’s disease and ulcerative colitis), with most of those patients showing clinical improvement also going into clinical remission. SSI are a complex biologic designed to reconstitute normal innate immune function through multiple parallel mechanisms.

Interaction of Cyclin-dependent kinase 2 with CR6-interacting factor 1, and the inhibitor search for such interaction against leukemia treatment resistance

Cyclin-dependent kinase-2 (CDK2) regulates cell cycle, whose structure and biological characteristics are well known. CRIF1 plays a regulatory role in the bone marrow microenvironment-induced leukemia cell cycle arrest through inhibiting CDK2. In this multi-disciplinary research, we will use a combined structure function study to reveal the interaction between CDK2 and CRIF1. This will facilitate the design of inhibitors for the interaction of the two important proteins, for eventual treatment of leukemia.

Characterization of molecular pathways mediating the effects of novel therapeutic agents in heart failure

Heart failure (HF) is a condition that develops after the heart becomes damaged or weakened. HF occurs when the pumping action of the heart is not strong enough to move blood around, especially during increased activity or under stress. In addition, the heart muscle may not relax properly to accommodate the flow of blood back from the lungs to the heart. These abnormalities in heart function can cause fluid to back up in lungs and in other parts of body.

Development and validation of blood-based biomarkers for improved heart failure management

Chronic heart failure (HF) is an epidemic affecting approximately 1.5-2% of Canada’s population (12% in patients over 80yrs) and the current one-year mortality rate after HF diagnosis remains disturbingly high at 25-40%. Even with treatment, many HF patients require hospitalizations during the course of their disease; in Canada HF is responsible for $3 billion in hospital costs annually.

SRRM4 protein purification and antibody production

The SRRM4 gene has been recently identified as a key protein responsible for a subtype of highly aggressive prostate cancers, called neuroendocrine prostate cancer (NEPC). Detection of SRRM4 protein in patient tumor biopsies is therefore important to predict and diagnose NEPC, so that early and more effective therapeutic means can be in place. Unfortunately, there is no SRRM4 antibody currently available that can be used for pathological analyses. This project will join force of academic and industrial expertise to develop a SRRM4 antibody that can be used in clinic for NEPC diagnosis.